Table of Contents PART 01: Executive summary  PART 02: Scope of the report  Market overview  Top-vendor offerings  PART 03: Market research methodology  Research methodology  Economic indicators  PART 04: Introduction  Key market highlights  PART 05: Disease overview  PART 06: Pipeline analysis  PART 07: Market landscape  Market overview  Five forces analysis  PART 08: Market segmentation by ROA  Oral anticoagulants  Injectable anticoagulants  PART 09: Market segmentation by drug class  Factor Xa inhibitors  DTIs  Heparin  Vitamin K antagonists  PART 10: Market segmentation by application  DVT  PE  AF  Others  PART 11: Geographical segmentation  Global anticoagulant market in Americas  Anticoagulant market in EMEA  Anticoagulant market in APAC  PART 12: Market drivers  Increasing demand for NOACs  Growing prevalence of coagulation disorders  Increase in hip and knee surgeries  PART 13: Impact of drivers  PART 14: Market challenges  Increasing cost of NOACs  Lack of antidotes in the market for NOACs  Patent expiry: a threat to market  PART 15: Impact of drivers and challenges  PART 16: Market trends  Strategic alliance  Increasing focus toward emerging economies  Patient assistance programs  PART 17: Vendor landscape  Competitive scenario  Other prominent vendors  PART 18: Key vendor analysis  Bayer HealthCare  Boehringer Ingelheim  Bristol-Myers Squibb  Daiichi Sankyo  Johnson & Johnson  Sanofi  PART 19: Appendix  List of abbreviations  PART 20: Explore Technavio  List of Exhibits Exhibit 01: Product offerings  Exhibit 02: Process of blood coagulation  Exhibit 03: Mechanism of action (MoA) of anticoagulant  Exhibit 04: Key customer segments of global anticoagulant market  Exhibit 05: Pipeline analysis 2016  Exhibit 06: Key pipeline molecules  Exhibit 07: Global anticoagulant market overview  Exhibit 08: Global anticoagulant market 2016-2021 ($ billions)  Exhibit 09: Five forces analysis  Exhibit 10: Segmentation of anticoagulant market based on ROA  Exhibit 11: Market share of anticoagulant based on ROA 2016  Exhibit 12: Types of heparin  Exhibit 13: Segmentation of anticoagulant market based on drug class  Exhibit 14: Market share of anticoagulant based on drug class 2016  Exhibit 15: Types of factor Xa inhibitors based on MOA  Exhibit 16: Factor Xa inhibitors in global anticoagulant market 2016-2021 ($ billions)  Exhibit 17: Types of DTIs based on MOA  Exhibit 18: DTIs in global anticoagulant market 2016-2021 ($ billions)  Exhibit 19: Global heparin market 2016-2021 ($ billions)  Exhibit 20: Global vitamin K antagonists market in 2016-2021 ($ billions)  Exhibit 21: Market segmentation by application  Exhibit 22: Market segmentation of anticoagulant based on application  Exhibit 23: Anticoagulant market in Americas 2016-2021 ($ billions)  Exhibit 24: Anticoagulant market in EMEA 2016-2021 ($ billions)  Exhibit 25: Anticoagulant market in APAC 2016-2021 ($ billions)  Exhibit 26: Impact of drivers  Exhibit 27: Patents to expire over forecast period  Exhibit 28: Impact of drivers and challenges  Exhibit 29: Competitive structure analysis of global anticoagulant market 2016  Exhibit 30: Competitive analysis of global anticoagulant market  Exhibit 31: Market share analysis 2016  Exhibit 32: Competitive landscape analysis 2016  Exhibit 33: Bayer HealthCare: Key highlights  Exhibit 34: Bayer HealthCare: Strength assessment  Exhibit 35: Bayer HealthCare: Strategy assessment  Exhibit 36: Bayer HealthCare: Opportunity assessment  Exhibit 37: Bayer HealthCare: YoY revenue and growth rate of XARELTO 2013-2015 ($ billions)  Exhibit 38: Boehringer Ingelheim: Key highlights  Exhibit 39: Boehringer Ingelheim: Strength assessment  Exhibit 40: Boehringer Ingelheim: Strategy assessment  Exhibit 41: Boehringer Ingelheim: Opportunity assessment  Exhibit 42: Boehringer Ingelheim: YoY revenue and growth rate of PRADAXA (global) 2013-2015 ($ billions)  Exhibit 43: Bristol-Myers Squibb: Highlights  Exhibit 44: Bristol-Myers Squibb: Strength assessment  Exhibit 45: Bristol-Myers Squibb: Strategy assessment  Exhibit 46: Bristol-Myers Squibb: Opportunity assessment  Exhibit 47: Bristol-Myers Squibb: YoY revenue and growth rate of ELIQUIS (global) 2013-2015 ($ millions)  Exhibit 48: Bristol-Myers Squibb: Geographic segmentation of ELIQUIS 2015  Exhibit 49: Daiichi Sankyo: Key highlights  Exhibit 50: Daiichi Sankyo: Strength assessment  Exhibit 51: Daiichi Sankyo: Strategy assessment  Exhibit 52: Daiichi Sankyo: Opportunity assessment  Exhibit 53: Johnson & Johnson: Strength assessment  Exhibit 54: Johnson & Johnson: Strategy assessment  Exhibit 55: Johnson & Johnson: Opportunity assessment  Exhibit 56: Sanofi: Key highlights  Exhibit 57: Sanofi: Strength assessment  Exhibit 58: Sanofi: Strategy assessment  Exhibit 59: Sanofi: Opportunity assessment  Exhibit 60: Sanofi: YoY revenue and growth rate of LOVENOX (global) 2013-2015 ($ billions)  Exhibit 61: Sanofi: Geographical segmentation of LOVENOX 2016  

Bayer HealthCare, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Johnson & Johnson, Sanofi, Abbott Vascular, Abiomed, AtriCure, Biosensors International, Biotronik, BioVentrix, C. R. Bard.